In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance.
Sign Up to like & getrecommendations! Published in 2019 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2019.119302
Abstract: Organ transplantation is the only effective method to treat end-stage organ failure. However, it is continuously plagued by immune rejection, which is mostly caused by T cell-mediated reactions. Dendritic cells (DCs) are professional antigen-presenting cells,… read more here.
Keywords: crispr cas9; gcd40; transplant; transplant tolerance ... See more keywords